Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis

Mult Scler. 1996 Jul;1(6):348. doi: 10.1177/135245859600100613.
No abstract available

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adjuvants, Immunologic / therapeutic use*
  • Double-Blind Method
  • Humans
  • Hydroxyquinolines / therapeutic use*
  • Multiple Sclerosis / drug therapy*
  • Recurrence
  • Remission Induction
  • Treatment Outcome

Substances

  • Adjuvants, Immunologic
  • Hydroxyquinolines
  • roquinimex